ANI Pharmaceuticals posted Q2 2026 net revenues of $266 million, up 25.9% year over year.
Net income available to common shareholders rose to $24.7 million; diluted GAAP EPS increased to $1.05.
Adjusted non-GAAP EBITDA climbed to $71.6 million, up 32.4%.
Cortrophin Gel net revenues jumped to $117.1 million, up 43.5%; ILUVIEN net revenues fell to $18.7 million, down 16.1% on timing of international shipments.
The company reaffirmed 2026 net revenue guidance of $1.08 billion-$1.14 billion; it cut Cortrophin Gel net revenue outlook to $520 million-$540 million.
ANIP•
